Enterococcus Bacteria for MRSA Infection Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The emergence of bacteria resistant to existing anti-MRSA drugs poses a challenge in effectively treating MRSA infections, necessitating the development of a novel protective agent.

Innovation Solution

Lactic acid bacteria belonging to the genus Enterococcus, such as Enterococcus faecalis, are used as a protective agent, either viable or killed, which can be administered as a medicine or food additive to prevent and treat MRSA infections, offering biological response modifier activity and resistance against MRSA.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing anti-MRSA drugs (vancomycin, teicoplanin, arbekacin, linezolid, daptomycin) are used for treatment, then MRSA infections can be treated, but bacteria resistant to these drugs emerge and treatment effectiveness decreases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddrug-resistant bacteria emergence

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the fundamental parameter of treatment approach by transitioning from chemical antibiotics to biological agents (Enterococcus bacteria). This parameter change allows exploitation of biological mechanisms (bacterial competition, immune modulation) that bypass traditional antibiotic resistance pathways, thereby maintaining treatment effectiveness while avoiding resistance development

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses viable or killed Enterococcus bacteria as a biological model to induce protective immunity. The bacteria serve as a biological copy or analog that triggers the host immune system to produce protective responses against MRSA, rather than directly killing the pathogen with antibiotics

Inventive Principle:

Principle #26Copying

2Adaptability or versatility

If novel anti-MRSA drugs are developed to overcome resistance, then treatment options increase, but the complexity of drug development and resistance monitoring increases

Engineering Contradiction:

Improvetreatment optionsVSAvoiddrug development complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The Enterococcus bacteria exhibit multi-functionality by simultaneously providing direct antimicrobial competition against MRSA, modulating host immune responses, and serving as a prophylactic agent. This single biological agent addresses multiple aspects of MRSA treatment, reducing the need for multiple different drugs and simplifying treatment protocols

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The Enterococcus bacteria possess inherent biological properties (competition for nutrients, production of antimicrobial substances, immune stimulation) that enable them to independently combat MRSA without requiring complex external delivery systems or combination therapies. The bacteria self-regulate their antimicrobial activity through natural biological mechanisms

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS10960034B2MRSA infection protective agent

Publication Date: 2021.03.30 NUTRI CO LTD

AI summary

Provided is a novel MRSA infection protective agent. Bacteria belonging to the genus Enterococcus have been found to be capable of protecting against MRSA infection. The MRSA infection protective agent comprises a bacterium belonging to the genus Enterococcus. Also provided are: a medicine for protection against MRSA infection, comprising a bacterium belonging to the genus Enterococcus; and a food for protection against MRSA infection, comprising a bacterium belonging to the genus Enterococcus.